Fred Alger Management, LLC Clovis Oncology, Inc. Transaction History

Fred Alger Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $106,341 - $582,394	-35,447 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$12.81 - $25.67 $704,088 - $1.41 Million	-54,964 Reduced 60.79%	35,447 $527,000
Q1 2019 May 14, 2019	BUY	$17.66 - $30.28 $213,950 - $366,842	12,115 Added 15.47%	90,411 $2.24 Million
Q4 2018 Feb 14, 2019	BUY	$11.63 - $32.67 $83,945 - $235,812	7,218 Added 10.16%	78,296 $1.41 Million
Q3 2018 Nov 14, 2018	SELL	$29.37 - $49.48 $2.97 Million - $5.01 Million	-101,278 Reduced 58.76%	71,078 $2.09 Million
Q2 2018 Jul 19, 2018	BUY	$42.06 - $62.4 $2.15 Million - $3.19 Million	51,054 Added 42.09%	172,356 $7.84 Million
Q1 2018 May 10, 2018	SELL	$50.12 - $67.72 $26.1 Million - $35.3 Million	-521,407 Reduced 81.13%	121,302 $6.41 Million
Q4 2017 Feb 14, 2018	SELL	$57.69 - $84.58 $10.7 Million - $15.7 Million	-185,698 Reduced 22.42%	642,709 $43.7 Million
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $55.6 Million - $70.3 Million	828,407	828,407 $68.3 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.